IL6 and multiple sclerosis: Dimethyl fumarate (DMF) (4, IC50 is 9.30 μM [52]) (detection of the inhibitory activity of DMF on IL-6 produced by lipopolysaccharide-induced dTHP-1 cell line using IL-6 commercial kits (Perkin Elmer) and the fluorescence method) is a US Food and Drug Administration (FDA)-approved synthetic drug used as an anti-inflammatory therapeutic for multiple sclerosis (MS) via Nrf2 inhibition of pathogenic inflammation [53,54], and it is currently in phase 2/3 clinical trials.